US 12,064,459 B2
Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
Robert M. Brucker, Melrose, MA (US); Xuecheng Zhang, Newton, MA (US); Ida Lister, Boston, MA (US); and Sanjay Jain, Shrewsbury, MA (US)
Assigned to DermBiont, Inc., Boston, MA (US)
Filed by DermBiont, Inc., Boston, MA (US)
Filed on Apr. 28, 2021, as Appl. No. 17/243,509.
Application 17/243,509 is a continuation of application No. 16/885,152, filed on May 27, 2020, granted, now 11,040,077.
Application 16/885,152 is a continuation of application No. PCT/US2020/027556, filed on Apr. 9, 2020.
Claims priority of provisional application 62/920,010, filed on Apr. 9, 2019.
Prior Publication US 2021/0361725 A1, Nov. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/747 (2015.01); A61K 8/49 (2006.01); A61K 8/99 (2017.01); A61K 9/00 (2006.01); A61K 35/741 (2015.01); A61K 35/744 (2015.01); A61P 17/00 (2006.01); A61P 31/04 (2006.01); A61Q 17/04 (2006.01); A61Q 19/08 (2006.01)
CPC A61K 35/747 (2013.01) [A61K 8/492 (2013.01); A61K 8/99 (2013.01); A61K 9/0014 (2013.01); A61K 35/741 (2013.01); A61K 35/744 (2013.01); A61P 17/00 (2018.01); A61P 31/04 (2018.01); A61Q 17/04 (2013.01); A61Q 19/08 (2013.01)] 19 Claims
 
1. A method of treating or inhibiting a symptom of a disease, disorder or condition associated with a topical pathogenic microorganism in a human subject, comprising administering to the human subject a composition formulated for topical application comprising an effective amount of human-derived Janthinobacterium lividum comprising the nucleic acid sequence consisting of SEQ ID NO: 5, wherein the topical pathogenic microorganism is selected from dermatophytes or gram-positive bacteria.